WHITE, Helen E, Matthew SALMON, Francesco ALBANO, Christina Sos Auour ANDERSEN, Stefan BALABANOV, Gueorgui BALATZENKO, Gisela BARBANY, Jean-Michel CAYUELA, Nuno CERVEIRA, Pascale COCHAUX, Dolors COLOMER, Daniel CORIU, Joana DIAMOND, Christian DIETZ, Stephanie DULUCQ, Marie ENGVALL, Georg N FRANKE, Egle GINEIKIENE-VALENTINE, Michal GNIOT, Maria Teresa GOMEZ-CASARES, Enrico GOTTARDI, Chloe HAYDEN, Sandrine HAYETTE, Andreas HEDBLOM, Anca ILEA, Barbara IZZO, Antonio JIMENEZ-VELASCO, Tomáš JURČEK, Veli KAIRISTO, Stephen E LANGABEER, Thomas LION, Nora MEGGYESI, Semir MESANOVIC, Luboslav MIHOK, Gerlinde MITTERBAUER-HOHENDANNER, Sylvia MOECKEL, Nicole NAUMANN, Olivier NIBOUREL, Oppliger Leibundgut ELISABETH, Panayiotis PANAYIOTIDIS, Helena PODGORNIK, Christiane POTT, Inmaculada RAPADO, Susan J ROSE, Vivien SCHAEFER, Tasoula TOULOUMENIDOU, Christopher VEIGAARD, Bianca VENNIKER-PUNT, Claudia VENTURI, Paolo VIGNERI, Ingvild VORKINN, Elizabeth WILKINSON, Renata ZADRO, Magdalena ZAWADA, Hana ZIZKOVA, Martin C MUELLER, Susanne SAUSSELE, Thomas ERNST, Katerina MACHOVA POLAKOVA, Andreas HOCHHAUS a Nicholas C P CROSS. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia. London: Nature Publishing Group, 2022, roč. 36, č. 7, s. 1834-1842. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-022-01607-z.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
Autoři WHITE, Helen E, Matthew SALMON, Francesco ALBANO, Christina Sos Auour ANDERSEN, Stefan BALABANOV, Gueorgui BALATZENKO, Gisela BARBANY, Jean-Michel CAYUELA, Nuno CERVEIRA, Pascale COCHAUX, Dolors COLOMER, Daniel CORIU, Joana DIAMOND, Christian DIETZ, Stephanie DULUCQ, Marie ENGVALL, Georg N FRANKE, Egle GINEIKIENE-VALENTINE, Michal GNIOT, Maria Teresa GOMEZ-CASARES, Enrico GOTTARDI, Chloe HAYDEN, Sandrine HAYETTE, Andreas HEDBLOM, Anca ILEA, Barbara IZZO, Antonio JIMENEZ-VELASCO, Tomáš JURČEK (203 Česká republika, domácí), Veli KAIRISTO, Stephen E LANGABEER, Thomas LION, Nora MEGGYESI, Semir MESANOVIC, Luboslav MIHOK, Gerlinde MITTERBAUER-HOHENDANNER, Sylvia MOECKEL, Nicole NAUMANN, Olivier NIBOUREL, Oppliger Leibundgut ELISABETH, Panayiotis PANAYIOTIDIS, Helena PODGORNIK, Christiane POTT, Inmaculada RAPADO, Susan J ROSE, Vivien SCHAEFER, Tasoula TOULOUMENIDOU, Christopher VEIGAARD, Bianca VENNIKER-PUNT, Claudia VENTURI, Paolo VIGNERI, Ingvild VORKINN, Elizabeth WILKINSON, Renata ZADRO, Magdalena ZAWADA, Hana ZIZKOVA, Martin C MUELLER, Susanne SAUSSELE, Thomas ERNST, Katerina MACHOVA POLAKOVA, Andreas HOCHHAUS a Nicholas C P CROSS (garant).
Vydání Leukemia, London, Nature Publishing Group, 2022, 0887-6924.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30205 Hematology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 11.400
Kód RIV RIV/00216224:14110/22:00128094
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1038/s41375-022-01607-z
UT WoS 000802314200002
Klíčová slova anglicky CML; molecular monitoring;standardization
Štítky 14110212, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 18. 1. 2023 13:06.
Anotace
Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the use of secondary, lyophilized cell-based BCR::ABL1 reference panels traceable to the World Health Organization primary reference material to standardize and validate local laboratory tests. Panels were used to assign and validate conversion factors (CFs) to the International Scale and assess the ability of laboratories to assess deep molecular response (DMR). The study also explored aspects of internal quality control. The percentage of EUTOS reference laboratories (n = 50) with CFs validated as optimal or satisfactory increased from 67.5% to 97.6% and 36.4% to 91.7% for ABL1 and GUSB, respectively, during the study period and 98% of laboratories were able to detect MR4.5 in most samples. Laboratories with unvalidated CFs had a higher coefficient of variation for BCR::ABL1(IS) and some laboratories had a limit of blank greater than zero which could affect the accurate reporting of DMR. Our study indicates that secondary reference panels can be used effectively to obtain and validate CFs in a manner equivalent to sample exchange and can also be used to monitor additional aspects of quality assurance.
VytisknoutZobrazeno: 1. 10. 2024 13:55